We believe that it might be possible to treat breast cancer— the leading cause of female cancer death — with a drug that can already be found in nearly every medicine cabinet in the world: Aspirin.
In 2010, we published an observational study in The Journal of Clinical Oncology showing that women with breast cancer who took aspirin at least once a week for various reasons were 50 percent less likely to die of breast cancer. In 2012, British researchers, by combining results from clinical trials that looked at using aspirin to prevent heart disease, found that aspirin was also associated with a significantly lower risk of breast cancer death.
And yet, until now, there have been no randomized trials (the gold standard of research) of aspirin use among women with breast cancer.
It's not hard to see why: Clinical trials are typically conducted on drugs developed by labs seeking huge profits. No one stands to make money off aspirin, which has been a generic drug since the Treaty of Versailles in 1919, and which costs less than $6 for a year's supply.
More ...
